349P Analysis of plasma angiogenesis factors on the efficacy of 2nd-line (2L) chemotherapy (chemo) combined with angiogenesis inhibitors (AIs) in metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study

Yuki, Satoshi; Yamazaki, K.; Sunakawa, Yu; Taniguchi, H.; Masuishi, T.; Shiozawa, Manabu; Bando, H.; Nishina, Tomohiro; Yasui, H.; Ohta, Takashi; Takahashi, Naoki; Denda, T.; Yoshida, Kazuhiro; Kato, Takeshi; Oki, Eiji; Okugawa, Yoshinaga; EBI, HIROMICHI; Abe, Y.; Nomura, Shosaku; Yoshino, T.

doi:10.1016/j.annonc.2022.07.487

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The GI-SCREEN CRC UKIT study evaluated the strength of interactions of pretreatment levels of 17 plasma angiogenesis factors (dichotomized according to the median value) on PFS in patients with mCRC treated with chemotherapy in combination with angiogenesis inhibitors [ 37 ]. Patients treated with chemotherapy plus bevacizumab and low PlGF had significantly longer PFS, and patients with high VEGF-A or low VEGF-D tended to have a better PFS [ 37 , 38 ]. However, no difference in PFS was observed between the high and low groups based on the PlGF, VEGF-A, and VEGF-D levels in this biomarker analysis.…”

Section: Discussionmentioning

confidence: 99%

Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer

Sunakawa,

Kuboki,

Watanabe

et al. 2024

Targ Oncol

View full text Add to dashboard Cite

Background The TRUSTY study evaluated the efficacy of second-line trifluridine/tipiracil (FTD/TPI) plus bevacizumab in metastatic colorectal cancer (mCRC). Objective This exploratory biomarker analysis of TRUSTY investigated the relationship between baseline plasma concentrations of angiogenesis-related factors and cell-free DNA (cfDNA), and the efficacy of FTD/TPI plus bevacizumab in patients with mCRC. Patients and Methods The disease control rate (DCR) and progression-free survival (PFS) were compared between baseline plasma samples of patients with high and low plasma concentrations (based on the median value) of angiogenesis-related factors. Correlations between cfDNA concentrations and PFS were assessed. Results Baseline characteristics ( n = 65) were as follows: male/female, 35/30; median age, 64 (range 25–84) years; and RAS status wild-type/mutant, 29/36. Patients in the hepatocyte growth factor (HGF)-low and interleukin (IL)-8-low groups had a significantly higher DCR (risk ratio [95% confidence intervals {CIs}]) than patients in the HGF-high (1.83 [1.12–2.98]) and IL-8-high (1.70 [1.02–2.82]) groups. PFS (hazard ratio {HR} [95% CI]) was significantly longer in patients in the HGF-low (0.33 [0.14–0.79]), IL-8-low (0.31 [0.14–0.70]), IL-6-low (0.19 [0.07–0.50]), osteopontin-low (0.39 [0.17–0.88]), thrombospondin-2-low (0.42 [0.18–0.98]), and tissue inhibitor of metalloproteinase-1-low (0.26 [0.10–0.67]) groups versus those having corresponding high plasma concentrations of these angiogenesis-related factors. No correlation was observed between cfDNA concentration and PFS. Conclusion Low baseline plasma concentrations of HGF and IL-8 may predict better DCR and PFS in patients with mCRC receiving FTD/TPI plus bevacizumab, however further studies are warranted. Clinical Trial Registration Number jRCTs031180122. Supplementary Information The online version contains supplementary material available at 10.1007/s11523-023-01027-8.

show abstract

Section: Discussionmentioning

confidence: 99%